ss-31 dosage: Frequently asked questions

Reduce the calculated dose by approximately 30–40% when switching from subcutaneous to intravenous routes due to complete bioavailability differences. Subcutaneous administration achieves roughly 60–70% bioavailability compared to IV, meaning a 0.25mg/kg subcutaneous dose produces similar plasma exposure to a 0.15–0.18mg/kg IV dose. However, peak concentration timing differs dramatically—IV bolus produces peak levels within 5 minutes followed by rapid decline, while subcutaneous dosing peaks at 15–30 minutes with more gradual clearance. For acute injury models where timing precision matters (ischemia-reperfusion, traumatic insult), IV dosing administered immediately before the intervention often produces more consistent results despite lower total dose.

Continuous protocols beyond 28 days require fresh reconstitution every 14 days to maintain potency. Do not rely on a single preparation for the full duration. Calculate total peptide needs for the entire study, divide into 14-day aliquots, and reconstitute each aliquot on a rolling schedule. For a 42-day protocol at 0.5mg/kg daily in a 250g rat (0.125mg per dose), you need approximately 5.25mg total; prepare three separate 2mg vials reconstituted on days 1, 15, and 29. This approach maintains potency above 95% throughout the study and prevents the 25–30% degradation that occurs when a single batch is used for 28+ days. Studies lasting 8–12 weeks should consider osmotic pump delivery to eliminate reconstitution frequency as a variable entirely.

Discard the vial and reconstitute a fresh batch. Peptide degradation at room temperature (20–25°C) exceeds 15% within 8 hours and 30–40% within 24 hours. The degradation products include fragmented peptide sequences that retain partial mitochondrial targeting ability but lack cristae-stabilising function, meaning bioassay results would show unpredictable mitochondrial outcomes. There is no reliable way to quantify remaining potency without mass spectrometry analysis, which costs more than replacing the preparation. Temperature excursions are the most common cause of protocol failures in multi-week SS-31 studies. If refrigeration reliability is uncertain, reconstitute smaller volumes more frequently rather than risk a large batch degrading.

Divide your total daily dose in half and administer every 12 hours starting immediately. No washout period is required because SS-31 tissue levels remain stable due to cardiolipin binding. If you were administering 1mg/kg once daily, switch to 0.5mg/kg every 12 hours. The transition maintains total daily exposure while reducing peak-trough variation, which improves mitochondrial cristae stabilisation consistency in models where sustained ATP production normalisation is the endpoint. Monitor for changes in oxidative stress markers during the first 48 hours post-transition, as shifting from bolus to divided dosing can temporarily alter ROS production patterns in tissues with marginal mitochondrial reserve.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.